tiprankstipranks
Organon (IT:1OGN)
:1OGN
Italy Market

Organon (1OGN) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1OGN Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Organon
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1OGN Stock 12 Month Forecast

There Are No Analyst Ratings for IT:1OGN In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

1OGN Financial Forecast

1OGN Earnings Forecast

Next quarter’s earnings estimate for 1OGN is €0.79 with a range of €0.79 to €0.79. The previous quarter’s EPS was €0.62. 1OGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year 1OGN has its overall industry.
Next quarter’s earnings estimate for 1OGN is €0.79 with a range of €0.79 to €0.79. The previous quarter’s EPS was €0.62. 1OGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year 1OGN has its overall industry.

1OGN Sales Forecast

Next quarter’s sales forecast for 1OGN is €1.39B with a range of €1.39B to €1.39B. The previous quarter’s sales results were €1.27B. 1OGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year 1OGN has its overall industry.
Next quarter’s sales forecast for 1OGN is €1.39B with a range of €1.39B to €1.39B. The previous quarter’s sales results were €1.27B. 1OGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year 1OGN has its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on IT:1OGN
Piper Sandler
Piper Sandler
€4.33€12.14
Hold
1.98%
Upside
Upgraded
04/28/26
Organon upgraded to Neutral from Underweight at Piper SandlerOrganon upgraded to Neutral from Underweight at Piper Sandler
Exane BNP Paribas Analyst forecast on IT:1OGN
Exane BNP Paribas
Exane BNP Paribas
€13€12.14
Hold
1.98%
Upside
Downgraded
04/28/26
Organon downgraded to Neutral from Outperform at BNP ParibasOrganon downgraded to Neutral from Outperform at BNP Paribas
Morgan Stanley Analyst forecast on IT:1OGN
Morgan Stanley
Morgan Stanley
€7.8
Hold
-34.44%
Downside
Reiterated
04/10/26
Morgan Stanley Reaffirms Their Hold Rating on Organon (OGN)
Evercore ISI Analyst forecast on IT:1OGN
Evercore ISI
Evercore ISI
Hold
Reiterated
04/10/26
Organon deal interest report bodes well for sector valuation, says Evercore ISIOrganon deal interest report bodes well for sector valuation, says Evercore ISI
Barclays
€6.5€6.93
Sell
-41.73%
Downside
Reiterated
02/24/26
Barclays Remains a Sell on Organon (OGN)
Bank of America Securities Analyst forecast on IT:1OGN
Bank of America Securities
Bank of America Securities
Sell
Reiterated
02/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (NYSE: OGN), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Vertex Pharmaceuticals (NASDAQ: VRTX)
J.P. Morgan Analyst forecast on IT:1OGN
J.P. Morgan
J.P. Morgan
€10.4€9.53
Sell
-19.88%
Downside
Reiterated
02/13/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP) and Organon (NYSE: OGN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on IT:1OGN
Piper Sandler
Piper Sandler
€4.33€12.14
Hold
1.98%
Upside
Upgraded
04/28/26
Organon upgraded to Neutral from Underweight at Piper SandlerOrganon upgraded to Neutral from Underweight at Piper Sandler
Exane BNP Paribas Analyst forecast on IT:1OGN
Exane BNP Paribas
Exane BNP Paribas
€13€12.14
Hold
1.98%
Upside
Downgraded
04/28/26
Organon downgraded to Neutral from Outperform at BNP ParibasOrganon downgraded to Neutral from Outperform at BNP Paribas
Morgan Stanley Analyst forecast on IT:1OGN
Morgan Stanley
Morgan Stanley
€7.8
Hold
-34.44%
Downside
Reiterated
04/10/26
Morgan Stanley Reaffirms Their Hold Rating on Organon (OGN)
Evercore ISI Analyst forecast on IT:1OGN
Evercore ISI
Evercore ISI
Hold
Reiterated
04/10/26
Organon deal interest report bodes well for sector valuation, says Evercore ISIOrganon deal interest report bodes well for sector valuation, says Evercore ISI
Barclays
€6.5€6.93
Sell
-41.73%
Downside
Reiterated
02/24/26
Barclays Remains a Sell on Organon (OGN)
Bank of America Securities Analyst forecast on IT:1OGN
Bank of America Securities
Bank of America Securities
Sell
Reiterated
02/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (NYSE: OGN), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Vertex Pharmaceuticals (NASDAQ: VRTX)
J.P. Morgan Analyst forecast on IT:1OGN
J.P. Morgan
J.P. Morgan
€10.4€9.53
Sell
-19.88%
Downside
Reiterated
02/13/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP) and Organon (NYSE: OGN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
TNYATenaya Therapeutics
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Organon

3 Months
Jason GerberryBank of America Securities
Success Rate
8/14 ratings generated profit
57%
Average Return
-3.90%
Copying Jason Gerberry's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of -3.90% per trade.
1 Year
Jason GerberryBank of America Securities
Success Rate
9/14 ratings generated profit
64%
Average Return
+11.80%
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +11.80% per trade.
2 Years
Jason GerberryBank of America Securities
Success Rate
9/14 ratings generated profit
64%
Average Return
+6.82%
Copying Jason Gerberry's trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +6.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1OGN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
1
1
0
0
Buy
0
0
0
0
0
Hold
6
4
4
0
0
Sell
4
1
1
0
0
Strong Sell
0
0
0
0
0
total
11
6
6
0
0
In the current month, 1OGN has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1OGN average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

1OGN Stock Forecast FAQ

What is IT:1OGN’s average 12-month price target, according to analysts?
Currently, no data Available
What is IT:1OGN’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IT:1OGN, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Organon a Buy, Sell or Hold?
      Currently, no data Available
      What is Organon’s share price target?
      Currently, no data Available
      What do analysts say about Organon?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Organon?
      To buy shares of IT:1OGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.